Low-density lipoprotein (LDL) uptake is one of a number of tests used to demonstrate hepatocyte-like function after stem cell differentiation. Use of two compounds, LDL and acetylated LDL (AcLDL), has been described despite each having different mechanisms of uptake. Three primary hepatocyte cultures and three sets of mesenchymal stromal cell (MSC) cultures, derived from both adipose tissue and bone marrow, were harvested from dogs. Those cells were compared to commercially available human and mouse bone marrow-derived MSCs. LDL receptor expression was demonstrated by gene expression and immunofluorescence in all primary hepatocyte cultures, undifferentiated canine bone marrow MSCs and canine adipose MSCs. Undifferentiated human and mouse bone marrow MSCs also expressed the LDL receptor. In vitro, canine hepatocytes took up labeled LDL, but not AcLDL. All undifferentiated MSCs took up LDL, but not AcLDL. In conclusion, LDL and not AcLDL is a test of canine hepatocyte-like phenotype, but this is not tissue or species specific and, therefore, is not informative assay when testing proof of MSC to hepatocyte differentiation.
Get full access to this article
View all access options for this article.
References
1.
PalakkanAA, HayDC, Anil KumarPR, KumaryTV and RossJA. (2013). Liver tissue engineering and cell sources: issues and challenges. Liver Int, 33:666–676.
2.
DalgettyDM, MedineCN, IredaleJP and HayDC. (2009). Progress and future challenges in stem cell-derived liver technologies. Am J Physiol Gastrointest Liver Physiol, 297:G241–G248.
3.
TiversMS, HandelI, GowAG, LipscombVJ, JalanR and MellanbyRJ. (2014). Hyperammonemia and systemic inflammatory response syndrome predicts presence of hepatic encephalopathy in dogs with congenital portosystemic shunts. PLoS One, 9:e82303.
4.
IjzerJ, SchotanusBA, Vander BorghtS, RoskamsTA, KisjesR, PenningLC, RothuizenJ and van den InghTS. (2010). Characterisation of the hepatic progenitor cell compartment in normal liver and in hepatitis: an immunohistochemical comparison between dog and man. Vet J, 184:308–314.
5.
SpeeB, ArendsB, van den InghTS, BrinkhofB, NederbragtH, IjzerJ, RoskamsT, PenningLC and RothuizenJ. (2006). Transforming growth factor beta-1 signalling in canine hepatic diseases: new models for human fibrotic liver pathologies. Liver Int, 26:716–725.
6.
FavierRP, SpeeB, SchotanusBA, van den InghTS, FietenH, BrinkhofB, ViebahnCS, PenningLC and RothuizenJ. (2012). COMMD1-deficient dogs accumulate copper in hepatocytes and provide a good model for chronic hepatitis and fibrosis. PLoS One, 7:e42158.
7.
KolaI. (2008). The state of innovation in drug development. Clin Pharmacol Ther, 83:227–230.
8.
GrahamMJ and LakeBG. (2008). Induction of drug metabolism: species differences and toxicological relevance. Toxicology, 254:184–191.
9.
GunawanBK and KaplowitzN. (2007). Mechanisms of drug-induced liver disease. Clin Liver Dis, 11:459–475, v.
10.
BerryMN and FriendDS. (1969). High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol, 43:506–520.
11.
ElautG, HenkensT, PapeleuP, SnykersS, VinkenM, VanhaeckeT and RogiersV. (2006). Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab, 7:629–660.
12.
DonatoMT, JoverR and Gomez-LechonMJ. (2013). Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr Drug Metab, 14:946–968.
13.
CrisanM, CorselliM, ChenCW and PeaultB. (2011). Multilineage stem cells in the adult: a perivascular legacy?. Organogenesis, 7:101–104.
14.
KangBJ, RyuHH, ParkSS, KoyamaY, KikuchiM, WooHM, KimWH and KweonOK. (2012). Comparing the osteogenic potential of canine mesenchymal stem cells derived from adipose tissues, bone marrow, umbilical cord blood, and Wharton's jelly for treating bone defects. J Vet Sci, 13:299–310.
15.
TakemitsuH, ZhaoD, YamamotoI, HaradaY, MichishitaM and AraiT. (2012). Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cells. BMC Vet Res, 8:150.
16.
ZhangZ, LiuJ, LiuY, LiZ, GaoWQ and HeZ. (2013). Generation, characterization and potential therapeutic applications of mature and functional hepatocytes from stem cells. J Cell Physiol, 228:298–305.
17.
BeerheideW, von MachMA, RingelM, FleckensteinC, SchumannS, RenzingN, HildebrandtA, BrennerW, JensenO, et al. (2002). Downregulation of beta2-microglobulin in human cord blood somatic stem cells after transplantation into livers of SCID-mice: an escape mechanism of stem cells?. Biochem Biophys Res Commun, 294:1052–1063.
18.
FanaliG, di MasiA, TrezzaV, MarinoM, FasanoM and AscenziP. (2012). Human serum albumin: from bench to bedside. Mol Aspects Med, 33:209–290.
19.
CampardD, LysyPA, NajimiM and SokalEM. (2008). Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology, 134:833–848.
20.
LeeKD, KuoTK, Whang-PengJ, ChungYF, LinCT, ChouSH, ChenJR, ChenYP and LeeOK. (2004). In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology, 40:1275–1284.
21.
ZemelR, BachmetovL, Ad-ElD, AbrahamA and Tur-KaspaR. (2009). Expression of liver-specific markers in naive adipose-derived mesenchymal stem cells. Liver Int, 29:1326–1337.
22.
HengstlerJG, BrulportM, SchormannW, BauerA, HermesM, NusslerAK, FandrichF, RuhnkeM, UngefrorenH, et al. (2005). Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin Drug Metab Toxicol, 1:61–74.
23.
MeierRP, MullerYD, MorelP, Gonelle-GispertC and BuhlerLH. (2013). Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence?. Stem Cell Res, 11:1348–1364.
24.
GoldsteinJL and BrownMS. (1987). Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation, 76:504–507.
25.
HoriuchiS, SakamotoY and SakaiM. (2003). Scavenger receptors for oxidized and glycated proteins. Amino Acids, 25:283–292.
26.
LiD and MehtaJL. (2005). Oxidized LDL, a critical factor in atherogenesis. Cardiovasc Res, 68:353–354.
27.
NahmiasY, CasaliM, BarbeL, BerthiaumeF and YarmushML. (2006). Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. Hepatology, 43:257–265.
28.
Harada-ShibaM, TakagiA, MarutsukaK, MoriguchiS, YagyuH, IshibashiS, AsadaY and YokoyamaS. (2004). Disruption of autosomal recessive hypercholesterolemia gene shows different phenotype in vitro and in vivo. Circ Res, 95:945–952.
29.
PrasajakP and LeeanansaksiriW. (2013). Developing a new two-step protocol to generate functional hepatocytes from Wharton's Jelly-derived mesenchymal stem cells under hypoxic condition. Stem Cells Int, 2013:762196.
30.
AsgariS, MoslemM, Bagheri-LankaraniK, PournasrB, MiryounesiM and BaharvandH. (2013). Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Stem Cell Rev, 9:493–504.
31.
PournasrB, MohamadnejadM, BagheriM, AghdamiN, ShahsavaniM, MalekzadehR and BaharvandH. (2011). In vitro differentiation of human bone marrow mesenchymal stem cells into hepatocyte-like cells. Arch Iran Med, 14:244–249.
32.
OuyangJF, LouJ, YanC, RenZH, QiaoHX and HongDS. (2010). In-vitro promoted differentiation of mesenchymal stem cells towards hepatocytes induced by salidroside. J Pharm Pharmacol, 62:530–538.
33.
SeglenPO. (1976). Preparation of isolated rat liver cells. Methods Cell Biol, 13:29–83.
34.
PfafflMW. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res, 29:e45.
35.
Hodgkiss-GeereHM, ArgyleDJ, CorcoranBM, WhitelawB, MilneE, BennettD and ArgyleSA. (2012). Characterisation and differentiation potential of bone marrow derived canine mesenchymal stem cells. Vet J, 194:361–368.
36.
AriasI, WolkoffA, BoyerJ, ShafritzD, FaustoN, AlterH and CohenD. (2011). The Liver: Biology and Pathobiology. Wiley, Chichester, UK.
37.
BabaevVR, KosykhVA, TsibulskyVP, IvanovVO, RepinVS and SmirnovVN. (1989). Binding and uptake of native and modified low-density lipoproteins by human hepatocytes in primary culture. Hepatology, 10:56–60.
38.
RequichaJF, ViegasCA, AlbuquerqueCM, AzevedoJM, ReisRL and GomesME. (2012). Effect of anatomical origin and cell passage number on the stemness and osteogenic differentiation potential of canine adipose-derived stem cells. Stem Cell Rev, 8:1211–1222.
39.
KianiC, ChenL, WuYJ, YeeAJ and YangBB. (2002). Structure and function of aggrecan. Cell Res, 12:19–32.
40.
SekiyaI, TsujiK, KoopmanP, WatanabeH, YamadaY, ShinomiyaK, NifujiA and NodaM. (2000). SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem, 275:10738–10744.
41.
de CrombruggheB, LefebvreV, BehringerRR, BiW, MurakamiS and HuangW. (2000). Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol, 19:389–394.
42.
ReichCM, RaabeO, WenischS, BridgerPS, KramerM and ArnholdS. (2012). Isolation, culture and chondrogenic differentiation of canine adipose tissue- and bone marrow-derived mesenchymal stem cells—a comparative study. Vet Res Commun, 36:139–148.
43.
VieiraNM, BrandaliseV, ZucconiE, SeccoM, StraussBE and ZatzM. (2010). Isolation, characterization, and differentiation potential of canine adipose-derived stem cells. Cell Transplant, 19:279–289.
44.
CsakiC, MatisU, MobasheriA, YeH and ShakibaeiM. (2007). Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study. Histochem Cell Biol, 128:507–520.
45.
InnesJF, GordonC, Vaughan-ThomasA, RhodesNP and CleggPD. (2013). Evaluation of cartilage, synovium and adipose tissue as cellular sources for osteochondral repair. Vet J, 197:619–624.
46.
RussellKA, GibsonTW, ChongA, CoC and KochTG. (2015). Canine platelet lysate is inferior to fetal bovine serum for the isolation and propagation of canine adipose tissue- and bone marrow-derived mesenchymal stromal cells. PLoS One, 10:e0136621.
47.
GuercioA, Di BellaS, CasellaS, Di MarcoP, RussoC and PiccioneG. (2013). Canine mesenchymal stem cells (MSCs): characterization in relation to donor age and adipose tissue-harvesting site. Cell Biol Int, 37:789–798.
48.
KanawaM, IgarashiA, RonaldVS, HigashiY, KuriharaH, SugiyamaM, SaskiantiT, PanH and KatoY. (2013). Age-dependent decrease in the chondrogenic potential of human bone marrow mesenchymal stromal cells expanded with fibroblast growth factor-2. Cytotherapy, 15:1062–1072.
49.
VolkSW, WangY and HankensonKD. (2012). Effects of donor characteristics and ex vivo expansion on canine mesenchymal stem cell properties: implications for MSC-based therapies. Cell Transplant, 21:2189–2200.
50.
ScrevenR, KenyonE, MyersMJ, YancyHF, SkaskoM, BoxerL, BigleyEC, 3rd, BorjessonDL and ZhuM. (2014). Immunophenotype and gene expression profile of mesenchymal stem cells derived from canine adipose tissue and bone marrow. Vet Immunol Immunopathol, 161:21–31.
51.
ZhangF, WangC, JingS, RenT, LiY, CaoY and LinJ. (2013). Lectin-like oxidized LDL receptor-1 expresses in mouse bone marrow-derived mesenchymal stem cells and stimulates their proliferation. Exp Cell Res, 319:1054–1059.
52.
ZhangF, WangC, WangH, LuM, LiY, FengH, LinJ, YuanZ and WangX. (2013). Ox-LDL promotes migration and adhesion of bone marrow-derived mesenchymal stem cells via regulation of MCP-1 expression. Mediators Inflamm, 2013:691023.
53.
LiesveldJL, AbboudCN, DuerstRE, RyanDH, BrennanJK and LichtmanMA. (1989). Characterization of human marrow stromal cells: role in progenitor cell binding and granulopoiesis. Blood, 73:1794–1800.
54.
HaniffaMA, CollinMP, BuckleyCD and DazziF. (2009). Mesenchymal stem cells: the fibroblasts' new clothes?. Haematologica, 94:258–263.
55.
DrevonCA, AttieAD, PangburnSH and SteinbergD. (1981). Metabolism of homologous and heterologous lipoproteins by cultured rat and human skin fibroblasts. J Lipid Res, 22:37–46.
56.
GrossD and WebbWW. (1986). Molecular counting of low-density lipoprotein particles as individuals and small clusters on cell surfaces. Biophys J, 49:901–911.
57.
QuaschningT, KonigerM, Kramer-GuthA, GreiberS, PavenstadtH, NauckM, SchollmeyerP and WannerC. (1997). Receptor-mediated lipoprotein uptake by human glomerular cells: comparison with skin fibroblasts and HepG2 cells. Nephrol Dial Transplant, 12:2528–2536.
58.
SasakiJ and CottamGL. (1982). Glycosylation of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta, 713:199–207.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
